The recommended dose of RINVOQ is 15 mg or 30 mg once daily based on individual patient presentation.

• A dose of 15 mg once daily is recommended for patients at higher risk of venous thromboembolism (VTE), major adverse cardiovascular events (MACE), and malignancy
• A dose of 30 mg once daily may be appropriate for patients with high disease burden who are not at higher risk of VTE, MACE, and malignancy or patients with an inadequate response to 15 mg once daily
• In adolescents (12 to 17 years of age) weighing at least 30 kg, a dose of 15 mg is recommended. If the patient does not respond adequately to 15 mg once daily, the dose can be increased to 30 mg once daily*
• The lowest effective dose to maintain response should be used
   

For patients ≥65 years of age, the recommended dose is 15 mg once daily.

Consideration should be given to discontinuing RINVOQ treatment in any patient who shows no evidence of therapeutic benefit after 12 weeks of treatment.

RINVOQ should only be used if no suitable treatment alternatives are available in patients¹:

• 65 years of age and older
• With a history of atherosclerotic cardiovascular disease or other cardiovascular risk factors (such as current or past long-time smokers)
• With malignancy risk factors (e.g., current malignancy or history of malignancy)

Administration

*The posology in adolescent patients 30 kg to <40 kg was determined using population pharmacokinetic modeling and simulation. No clinical exposure data are available in adolescents <40 kg. The safety and efficacy of RINVOQ in children with atopic dermatitis below the age of 12 years have not been established. No data are available. ^†Topical calcineurin inhibitors may be used for sensitive areas such as the face, neck, and intertriginous and genital areas.¹

 ^§§ELEVATE: AbbVie defines "ELEVATE" as the raising of the standards of care in AD patients, measured by WP-NRS and EASI score, treated with Dupilumab vs RINVOQ at week 16 of the head to head trials.^2,3